{
    "data": [
        {
            "id": "4511620",
            "title": "National Beverage begins stock buyback amid market headwinds",
            "description": "<html><body><ul>\n<li>National Beverage (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/FIZZ\" title=\"National Beverage Corp.\">FIZZ</a></span>) on Thursday said it had begun open market purchases of its common stock under its previously announced share repurchase program.</li>\n<li>The company said it remains financially strong despite pressures from geopolitical factors, a U.S. government shutdown, tariffs, and weaker consumer spending affecting the beverage sector.</li>\n<li>National Beverage said it views current market conditions as temporary and believes its shares are undervalued.</li>\n<li>FIZZ is <span style=\"color: green;\">+2.30%</span> to $33.22.</li>\n<li>Source: <a href=\"https://seekingalpha.com/pr/20286940-national-beverage-corp-announces-commencement-of-stock-buyback-and-addresses-market\">Press Release</a>\n</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511620-national-beverage-begins-stock-buyback-amid-market-headwinds",
            "pub_date": "2025-10-31 01:56:02",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511618",
            "title": "NN projects $40M in new program run-rate through 2026 launches as M&A and refinancing efforts intensify",
            "description": "<html><body><p>Earnings Call Insights: NN, Inc. (NNBR) Q3 2025</p>\n<h3>Management View</h3>\n<ul>\n<li>CEO Harold Bevis emphasized the company's structured sales growth program, reporting over $180 million in new business secured and a sales pipeline now over $850 million with a closed opportunity hit rate above 20%. Bevis stated, \"We've had no cancellations of any of these new wins, just some pushouts.\" He highlighted foundational wins in defense and medical, each potentially contributing over $5 million annually and noted the company is at \"the bottom of the bathtub curve for our served markets and customers.\"</li>\n<li>The company is actively pursuing strategic M&amp;A, evaluating multiple acquisition targets to accelerate growth and scale, while formally initiating refinancing discussions for its preferred equity. Bevis explained, \"We're getting ready to embark upon that now...any acquisition we do of any size at all requires a refinancing discussion.\"</li>\n<li>Quarterly sales were reported at $104 million, with growth in power solutions and aerospace, defense, and electronics offset by headwinds in mobile solutions and automotive rationalization. Adjusted operating income reached $4 million, and adjusted EBITDA increased 7.9% year-over-year on a lower sales base. \"Our margin is up 170 basis points year-over-year,\" said Bevis, also noting $9 million in free cash flow generation.</li>\n<li>CFO Christopher Bohnert detailed, \"Net sales for the quarter were $103.9 million, declining $9.7 million versus last year's third quarter...adjusted operating income for the third quarter was $4 million, marking a strong increase...compared to $1.3 million in the prior year third quarter.\"</li>\n<li>COO Tim French stated, \"Our adjusted EBITDA margins have expanded 260 basis points since the launch of our transformational plan in early '23...We've reduced our overall headcount by more than 20%, more appropriately aligning our resources to the needs of the company.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Bevis reiterated guidance with a slight reduction in sales outlook due to lower automotive expectations, balanced by higher defense projections, resulting in minimal impact to gross margin dollars: \"We're lowering them a bit...lowering our outlook for automotive but increasing our outlook in defense.\"</li>\n<li>The company remains on track to achieve its target for new wins, with a pipeline exceeding $750 million and the largest portion not tied to automotive. Bevis stated, \"We're on track.\"</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Net sales for the quarter were $103.9 million. Adjusted operating income was $4 million, up from $1.3 million in the prior year. Adjusted EBITDA reached $12.4 million, with margins at 11.9% of net sales, a 170-basis point increase year-over-year.</li>\n<li>In the Power Solutions segment, net sales were $44.9 million, up from $42.9 million last year. Adjusted EBITDA for this segment was $8.9 million, with margins rising approximately 500 basis points year-over-year.</li>\n<li>The Mobile Solutions segment saw net sales of $59.1 million, compared to $70.7 million last year, mainly due to rationalization and lower North American volumes. Adjusted EBITDA was $6.7 million, with margins at 11.4%.</li>\n<li>Free cash flow for the quarter was $9 million, with net working capital below $80 million, a 21% improvement from Q2 '23.</li>\n<li>Over 100 new programs are set to launch in 2025, with more than 70 scheduled for 2026. Forecasted contribution is approximately $26 million for 2025 and an estimated $40 million at full run-rate.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Robert Brown, Lake Street Capital: Asked about data center demand in power solutions and gross margin targets. Bevis responded that data center needs are driving grid demand, despite federal funding delays, and cited gold prices as a variable affecting margins.</li>\n<li>John Franzreb, Sidoti: Inquired about revenue forecast adjustments and facility rationalization impact. Bevis said rationalization will be a 2026 event with no 2025 sales impact. On capacity utilization, French indicated significant available capacity, with power at about 60% utilization and mobile varying by facility.</li>\n<li>Franzreb also asked about M&amp;A versus preferred elimination. Bevis stressed both are priorities, with no single path chosen and external advisory support being assembled.</li>\n<li>Michael Crawford, B. Riley: Queried about China operations and free cash flow expectations. Bevis described the China JV as successful, with $130 million in sales and over $30 million in EBITDA. Looking ahead, Bevis expects free cash flow to strengthen in 2026, targeting around $10 million absent the CARES refund.</li>\n<li>Barry Haimes, Sage Asset: Asked about 2026 expectations. Bevis described regional automotive growth variations and highlighted that foundational wins in medical and defense will support segment growth, with commercial vehicle improvement anticipated in the second half.</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts maintained a constructive but cautious tone, focusing on segment performance, capital allocation, and execution of growth and cost initiatives. Questions sought clarity on guidance, margin drivers, and capacity, reflecting a neutral to slightly positive sentiment.</li>\n<li>Management's tone was confident in prepared remarks, frequently referencing progress and strategic wins. In Q&amp;A, responses became more detailed and occasionally cautious, especially when addressing sector headwinds and macro uncertainty. Bevis acknowledged, \"We're not at liberty to discuss the plant,\" and \"We're not sitting on a big pile of cash,\" indicating some defensiveness.</li>\n<li>Compared to the previous quarter, management maintained a similar level of confidence, but with heightened attention to mix shifts and external headwinds. Analysts' tone remained consistently inquisitive, with continued focus on execution and risk management.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>The company reduced its sales outlook due to automotive softness but increased defense expectations. Portfolio mix shifts were highlighted as a mitigating factor for margins.</li>\n<li>Strategic focus has shifted further toward M&amp;A and refinancing activities, with management reporting meaningful progress in pipeline development and organization.</li>\n<li>Analysts continued to focus on margin expansion, capital structure optimization, and the ramp-up of new business, similar to the previous quarter.</li>\n<li>Adjusted EBITDA margins and free cash flow both improved sequentially, while leadership reiterated long-term margin targets and confidence in transformation programs.</li>\n<li>Management's tone in both quarters reflected ongoing confidence, but the current quarter showed increased transparency about macro risks and operational adjustments.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management cited softness in the North American automotive market, volatility in electrical infrastructure funding, high inflation in precious metals, and commercial vehicle industry recalibration as ongoing headwinds.</li>\n<li>Mitigation efforts include cost reductions, working capital improvements, focused new business development, and continued rationalization of underperforming assets.</li>\n<li>Analysts raised concerns about the pace of M&amp;A, timing of facility rationalizations, and the impact of federal funding delays.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>NN, Inc. management underscored that while market headwinds and sector volatility persist, the company is driving margin and cash flow improvements through operational restructuring, disciplined cost management, and an aggressive new business acquisition program. With foundational wins in key growth sectors, ongoing strategic M&amp;A and refinancing initiatives, and a robust pipeline of program launches expected to deliver up to $40 million in new run-rate revenues, leadership maintains a positive outlook for sustainable value creation through 2026 and beyond.</p>\n<p><a href=\"https://seekingalpha.com/symbol/nnbr/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511618-nn-projects-40m-in-new-program-run-rate-through-2026-launches-as-m-and-a-and-refinancing",
            "pub_date": "2025-10-31 01:50:42",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511597",
            "title": "Tech Voices: China, Bessent on TikTok deal; OpenAI's IPO",
            "description": "<html><body><p dir=\"ltr\"><em>Seeking Alpha's roundup of statements, announcements, and remarks that could impact the technology sector.</em></p>\n<ul><li dir=\"ltr\">China plans to work with the U.S. to resolve issues related to TikTok's U.S. operations, which are currently owned by China's ByteDance (<a href=\"https://seekingalpha.com/symbol/BDNCE\" title=\"ByteDance\">BDNCE</a>).</li></ul>\n<p dir=\"ltr\">\"Both sides further affirmed the outcomes of the Madrid trade consultations, with the U.S. side making positive commitments in areas such as investment, and China agreeing to work with the U.S. to properly resolve issues related to TikTok,\" China's Commerce Ministry <a href=\"https://www.mofcom.gov.cn/xwfb/xwfyrth/art/2025/art_c42035acf50846ffb9fb4761ee224faf.html\" rel=\"nofollow\">said in a statement</a>.</p>\n<p dir=\"ltr\">The announcement comes in the wake of trade talks between U.S. and Chinese representatives in Kuala Lumpur earlier this week. </p>\n<ul><li dir=\"ltr\">Meanwhile, Treasury Secretary Scott Bessent said the Chinese government has okayed the transfer of TikTok's U.S. operations, but didn't disclose any details.</li></ul>\n<p dir=\"ltr\">\"In Kuala Lumpur, we finalized the TikTok agreement in terms of getting Chinese approval, and I would expect that would go forward in the coming weeks and months, and we'll finally see a resolution to that,\" Bessent said, <a href=\"https://www.reuters.com/world/china/china-us-trade-deal-could-be-signed-next-week-us-treasurys-bessent-says-2025-10-30/\" rel=\"nofollow\">according to Reuters</a>.</p>\n<ul><li dir=\"ltr\">OpenAI (<a href=\"https://seekingalpha.com/symbol/OPENAI\" title=\"OpenAI\">OPENAI</a>) is readying an IPO that could value the AI developer as high as $1 trillion. </li></ul>\n<p dir=\"ltr\">The company is considering aiming to raise at least $60 billion through the deal. OpenAI could file for the IPO as soon as the second half of 2026, <a href=\"https://www.reuters.com/world/china/china-us-trade-deal-could-be-signed-next-week-us-treasurys-bessent-says-2025-10-30/\" rel=\"nofollow\">according to Reuters</a>, who cited people close to the deal. </p>\n<p dir=\"ltr\">OpenAI counts Microsoft (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/MSFT\" title=\"Microsoft Corporation\">MSFT</a></span>) as a major investor.</p>\n<p><strong id=\"docs-internal-guid-5d773449-7fff-45cd-d593-8e225ed27fc5\"></strong></p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511597-tech-voices-china-bessent-on-tiktok-deal-openais-ipo",
            "pub_date": "2025-10-31 01:50:42",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511609",
            "title": "Technip Energies reports revenue of €5.4B for first nine months of 2025",
            "description": "<html><body><ul>\n<li>Technip Energies N.V. <a href=\"https://seekingalpha.com/pr/20285604-technip-energies-financial-results-for-the-first-nine-months-of-2025\">press release</a>  (THNPF): Revenue rose 9% Y/Y to €5.4B for first nine months of 2025.</li>\n<li>Diluted earnings per share was  €1.58.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511609-technip-energies-reports-revenue-of-54b-for-first-nine-months-of-2025",
            "pub_date": "2025-10-31 01:45:50",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511610",
            "title": "IQSTEL sees $430 million in organic revenue for 2026",
            "description": "<html><body><ul> <li>IQSTEL (<a href=\"https://seekingalpha.com/symbol/IQST\">IQST</a>) on Thursday announced its 2026 organic revenue forecast of $430 million, representing a 26% increase over the company's $340 million revenue forecast for 2025.</li> <li>IQSTEL has reaffirmed its revenue guidance of $340 million for 2025, on the back of continued organic expansion across its Telecom, Fintech, Artificial Intelligence (AI), and Cybersecurity services.</li> <li>The company also reiterated its strategic plan to acquire two to three accretive businesses as part of its roadmap to achieve $15 million in EBITDA by 2026, while maintaining a clear focus on profitable organic growth.</li> <li>Source: <a href=\"https://seekingalpha.com/pr/20286471-iqst-iqstel-announces-430-million-organic-revenue-forecast-for-2026-reflecting-26-percent\">Press Release</a>\n</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511610-iqstel-sees-430-million-in-organic-revenue-for-2026",
            "pub_date": "2025-10-31 01:45:50",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511603",
            "title": "Merck outlines $50B growth opportunity by mid-2030s as pipeline and new launches accelerate",
            "description": "<html><body><p>Earnings Call Insights: Merck &amp; Co., Inc. (MRK) Q3 2025</p>\n<h3>Management View</h3>\n<ul>\n<li>CEO Robert Davis stated that \"We continue to make meaningful progress in using the power of leading-edge science to save and improve lives around the world,\" highlighting approximately 80 Phase III trials across diverse therapeutic areas and investments behind more than 20 launch opportunities. Davis noted the completion of the strategic acquisition of Verona Pharma and described it as providing \"another important growth driver with multibillion-dollar commercial potential into the next decade.\"</li>\n<li>Davis emphasized, \"We're making strong progress across the business, and I remain confident in our ability to further broaden our impact to patients and deliver long-term growth and value for shareholders.\" He also referenced ongoing engagement with the U.S. administration regarding healthcare policy and announced a \"broader plan that will result in the investment of more than $70 billion in expanded domestic manufacturing and R&amp;D.\"</li>\n<li>CFO Caroline Litchfield reported, \"Total company revenues were $17.3 billion, an increase of 4% or 3% excluding the impact of foreign exchange.\" Litchfield added, \"We delivered solid performance in the quarter, with growth driven by continued strength in Oncology and Animal Health as well as increasing contributions from our many new product launches.\" She confirmed EPS of $2.58 for the quarter and highlighted a gross margin of 81.9%, an increase of 1.4 percentage points.</li>\n<li>Litchfield provided guidance for 2025: \"We expect full year revenue to be between $64.5 billion and $65 billion,\" with EPS guidance of $8.93 to $8.98 and a gross margin assumption of approximately 82%.</li>\n<li>Executive VP Dean Li highlighted clinical and regulatory milestones, including FDA approval for KEYTRUDA QLEX and positive top line results from the CORALreef Lipids trial for enlicitide. He underscored the expansion of the immunology pipeline and described OHTUVAYRE, acquired through Verona, as a \"first-in-class dual phosphodiesterase 3 and 4 inhibitor for the maintenance treatment of chronic obstructive pulmonary disease.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Litchfield stated, \"We expect full year revenue to be between $64.5 billion and $65 billion,\" and EPS guidance of $8.93 to $8.98, noting the range includes a negative impact from foreign exchange and a benefit from the restructured agreement for Koselugo. The guidance now incorporates the Verona Pharma acquisition and the restructured Koselugo agreement. She added, \"As we look to 2026, we expect an acceleration in underlying operating expense growth driven by investments in both R&amp;D and SG&amp;A to fuel our pipeline and new launches, including more than $0.5 billion of investment to maximize the potential of OHTUVAYRE.\"</li>\n<li>Management maintained its commitment to its dividend and continued pace of share repurchases, expecting approximately $5 billion for the full year.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Revenues for the third quarter were $17.3 billion. Oncology sales, led by KEYTRUDA, increased 8% to $8.1 billion, with growth from both metastatic and earlier-stage cancers. WELIREG sales rose 41% to $196 million. GARDASIL sales were $1.7 billion, down 25%, with U.S. growth offset by declines in Japan and China. CAPVAXIVE sales reached $244 million, and ENFLONSIA recorded $79 million in initial sales. WINREVAIR saw global sales of $360 million, with a noted timing impact from distributor purchases. Animal Health sales increased 7%. Gross margin was reported at 81.9%, and operating expenses were $6.6 billion, including $300 million in business development charges.</li>\n<li>Litchfield highlighted, \"Our current guidance midpoint of $8.96 reflects a benefit from the restructured agreement for Koselugo of $0.09, partially offset by an estimated negative impact related to the acquisition of Verona of $0.04.\"</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Asad Haider, Goldman Sachs: Asked about business development priorities and potential for transformative deals. Davis responded that Merck seeks opportunities aligned with key therapeutic areas, focusing on deals in the $1 billion to $15 billion range but is open to larger transactions if science and value align. \"Our focus will be on bringing in pipeline assets, not on those types of deals.\"</li>\n<li>Geoffrey Meacham, Citigroup: Inquired about expanding development of TL1A immunology. Li explained the move into rheumatology and dermatology, emphasizing the importance of Phase III trials in Crohn's and SSc-ILD.</li>\n<li>Akash Tewari, Jefferies: Queried about the solid tumor strategy and the relative excitement for TROP2 vs. PD-1 VEGF. Li said Merck is \"extremely excited about the TROP2, the sac-TMT,\" and is eager to see results in broader settings.</li>\n<li>Evan Seigerman, BMO: Sought updates on ENFLONSIA's U.S. launch. Davis noted a later launch into the season but stated, \"We feel good about where we are with ENFLONSIA\" and expect increasing impact into 2026. Litchfield added, \"Feedback from customers has been very good.\"</li>\n<li>Daina Graybosch, Leerink: Asked about KEYTRUDA's early-stage sales. Davis reported more than half of KEYTRUDA's growth is from earlier-stage indications, exceeding 25% of total sales.</li>\n<li>Chris Schott, JPMorgan: Sought updates on MFN policy. Davis said, \"We are in continuing discussions with the administration\" and is \"very optimistic that we're going to have a constructive outcome.\"</li>\n<li>Carter Gould, Cantor: Inquired about WELIREG and overall survival data. Li stressed the importance of OS and expressed eagerness for future results.</li>\n<li>Terence Flynn, Morgan Stanley: Asked about 2026 top line expectations. Litchfield projected solid growth fueled by new launches and acknowledged headwinds from loss of exclusivity and IRA price setting.</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts focused on business development, pipeline progress, and policy risks, with a neutral to slightly positive tone, probing for strategic clarity and competitive positioning.</li>\n<li>Management maintained a confident and optimistic outlook in both prepared remarks and Q&amp;A, using phrases like \"we remain highly focused\" and \"I remain confident.\" During Q&amp;A, management continued to project confidence, though occasionally more cautious or measured when addressing policy and pricing questions.</li>\n<li>Compared to the previous quarter, the tone is steady, with continued emphasis on pipeline strength and new launches. Analysts' tone remains inquisitive but balanced, while management sustains a theme of constructive optimism.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Guidance for full-year revenue and EPS was reaffirmed, now including Verona Pharma and Koselugo impacts, with minor adjustments for FX and acquisition effects. In Q2, Verona Pharma was an announced but pending acquisition, now completed and integrated into guidance.</li>\n<li>Oncology growth remains a key driver, with continued strong performance for KEYTRUDA and WELIREG. New product launches (WINREVAIR, CAPVAXIVE, ENFLONSIA) are contributing more meaningfully, and OHTUVAYRE is now incorporated following the Verona acquisition.</li>\n<li>Strategic focus has shifted to executing and integrating recent deals, further broadening the pipeline and investing in manufacturing.</li>\n<li>Analysts have maintained focus on product launches, business development, and policy headwinds. Management’s confidence in pipeline execution and future growth remains consistent with the prior quarter.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Management noted potential headwinds from U.S. healthcare policy, price pressures, and loss of exclusivity for key products such as DIFICID, BRIDION, and JANUVIA. Litchfield stated, \"We do expect some headwind from price in our ex-U.S. markets.\"</li>\n<li>The potential impact of government reforms and pricing changes was raised by both management and analysts, with ongoing discussions highlighted but no concrete resolutions yet.</li>\n<li>Competition in both human and animal health segments, as well as in vaccines (e.g., VAXNEUVANCE in Japan), was specifically mentioned.</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Management underscores the transformation underway at Merck, with growing contributions from a diversified portfolio, ongoing strategic acquisitions like Verona Pharma, and a robust pipeline of over 80 Phase III trials. The company stresses its ability to drive long-term growth and value for shareholders by investing in innovation, executing new product launches, and maintaining strategic discipline in business development. The outlook remains confident, backed by strong third-quarter results, expanding manufacturing investments, and clear guidance for the year.</p>\n<p><a href=\"https://seekingalpha.com/symbol/mrk/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511603-merck-outlines-50b-growth-opportunity-by-midminus-2030s-as-pipeline-and-new-launches",
            "pub_date": "2025-10-31 01:40:49",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511605",
            "title": "Cogeco Non-GAAP EPS of C$2.12, revenue of C$731.4M",
            "description": "<html><body><ul>\n<li>Cogeco <a href=\"https://seekingalpha.com/pr/20285519-cogeco-announces-q4-2025-financial-results\">press release</a>  (CGECF): Q4 Non-GAAP EPS of C$2.12.</li>\n<li>Revenue of C$731.4M (-4.9% Y/Y).</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511605-cogeco-non-gaap-eps-of-c212-revenue-of-c7314m",
            "pub_date": "2025-10-31 01:40:49",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511591",
            "title": "DBV Technologies announces $30 million ADS sale",
            "description": "<html><body><ul>\n<li>DBV Technologies (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/DBVT\" title=\"DBV Technologies S.A.\">DBVT</a></span>) announced on Thursday that it has agreed to issue and sell new ordinary shares in the form of American Depositary Shares ((ADSs)), for total gross proceeds to the company of approximately $30 million through Citizens Capital Markets, acting as sales agent.</li>\n<li>The ADSs will be admitted to trading on Nasdaq Capital Market and the new ordinary shares on Euronext Paris.</li>\n<li>Under the ATM Program, 10.71 million new ordinary shares (underlying 2.14 million new ADSs) will be issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling certain characteristics at an at-the-market price of $14.00 per ADS.</li>\n<li>Each ADS giving the right to receive five ordinary shares of the company, representing a discount as well as foreign exchange effects, of 4.89% to the last closing price of the company’s shares on the regulated market of Euronext in <span class=\"location\">Paris </span>preceding the setting of the issue price, said the company. </li>\n<li>The issuance and delivery of the new ordinary shares is expected to take place on October 31, 2025.</li>\n<li>The new ordinary shares will represent 6.34% of the existing shares already admitted to trading on Euronext Paris, representing, together with the ordinary shares issued without a French listing prospectus or an exemption document over a rolling period of 12 months, less than 30% of the ordinary shares already admitted to trading on Euronext Paris.</li>\n<li>The new ordinary shares will represent a dilution of approximately 5.96% upon completion of the transaction.</li>\n<li>DBVT is <span style=\"color: red;\">-6.04%</span> to $14.29.</li>\n<li>Source: <a href=\"https://seekingalpha.com/pr/20285486-dbv-technologies-announces-sale-of-approximately-30-million-of-adss-through-its-at-the-market\">Press Release</a>\n</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511591-dbv-technologies-announces-30-million-ads-sale",
            "pub_date": "2025-10-31 01:35:49",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511598",
            "title": "Spin Master Non-GAAP EPS of $1.11, revenue of $734.7M",
            "description": "<html><body><ul>\n<li>Spin Master <a href=\"https://seekingalpha.com/pr/20285807-spin-master-reports-q3-2025-financial-results\">press release</a>  (TOY:CA): Q3  Non-GAAP EPS of $1.11.</li>\n<li>Revenue of $734.7M, a decrease of 17%, primarily driven by a decrease in Toy Revenue.</li>\n</ul>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511598-spin-master-non-gaap-eps-of-1_11-revenue-of-734_7m",
            "pub_date": "2025-10-31 01:35:49",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4511594",
            "title": "Acadian outlines record $39B gross sales in 2025 as AUM reaches all-time high, with enhanced and extension strategies fueling momentum",
            "description": "<html><body><p>Earnings Call Insights: Acadian Asset Management Inc. (AAMI) Q3 2025</p>\n<h3>Management View</h3>\n<ul>\n<li>Kelly Ann Young, CEO, stated that \"every milestone we hit reflects our team's discipline and dedication in executing the organic growth plan we articulated when I assumed the CEO role at the beginning of the year.\" She highlighted that Acadian managed $166.4 billion of AUM as of September 30, 2025, and that \"95% of our strategies by revenue have outperformed benchmarks over a 5-year period with a 4.5% annualized excess return.\"</li>\n<li>Young emphasized product and distribution initiatives, with $6.4 billion of positive net client cash flows in Q3 2025, representing 4% of beginning-period AUM, and described it as \"the second highest in the firm's history, driven by enhanced extension and core strategies such as non-U.S. equities.\"</li>\n<li>She also noted that \"AUM surged to $166.4 billion as of September 30, 2025, marking another record high for Acadian.\"</li>\n<li>The CEO underscored a robust distribution platform, reporting $39 billion of gross sales in the first 9 months of 2025, surpassing the previous annual sales record of $21 billion set in 2024.</li>\n<li>Scott Hynes, CFO, stated, \"Q3 '25 ENI revenue of $136 million increased from Q3 '24 by 12%, primarily due to management fee growth, partially offset by a decline in performance fees. Management fees increased 21% from Q3 '24, reflecting a 34% increase in average AUM driven by strong positive NCCF and market appreciation.\"</li>\n<li>Hynes added, \"Our Q3 '25 ENI operating margin expanded 157 basis points to 33.2% from 31.7% in Q3 '24 driven by increased ENI management fees.\"</li>\n</ul>\n<h3>Outlook</h3>\n<ul>\n<li>Hynes indicated, \"We now expect that our fiscal year 2025 operating expense ratio will be approximately 44% to 46%, and while our fiscal year 2025 variable compensation ratio is now expected to be approximately 43% to 45%.\"</li>\n<li>The CEO described the pipeline as \"robust after the funding of several large mandate wins in Q3 of 2025.\"</li>\n<li>Management suggested that the drive toward a 50-50 split of AUM between U.S. and non-U.S. clients remains a key target.</li>\n<li>Hynes noted flexibility with the $200 million Term Loan A and ongoing review of capital allocation each quarter.</li>\n</ul>\n<h3>Financial Results</h3>\n<ul>\n<li>Young recapped, \"Q3 '25 financial results included record management fees of $136.1 million, up 21% from Q3 of '24 million. ENI EPS of $0.76, up 29% from Q3 '24, and operating margin expansion to 33.2%, up from 31.7% in Q3 of '24.\"</li>\n<li>Positive net flows of $6.4 billion in Q3 2025 were described as the second highest in company history.</li>\n<li>The CFO reported the repurchase of 0.1 million shares or $5 million of stock at a volume weighted average price of $48.58. An interim dividend of $0.01 per share was declared.</li>\n<li>Gross debt outstanding declines from $275 million to $200 million with the announced refinancing.</li>\n</ul>\n<h3>Q&amp;A</h3>\n<ul>\n<li>Kenneth Lee, RBC Capital Markets: Asked about the institutional pipeline composition and strategy demand. Young replied, \"enhanced equity continues to resonate with a number of our clients... we've seen a real pickup of interest... in our extension strategies... the pipeline looks very diverse by strategy, continues to look very diverse by client domicile.\"</li>\n<li>Lee followed up on capital management and debt strategy. Hynes answered, \"we feel really good about the senior notes redemption... we'll be looking again every quarter... a lot of flexibility there for us to repay early, no fees or costs associated with that.\"</li>\n<li>Lee also inquired about the pickup in gross inflows. Young stated, \"we've very thoughtfully added resources to our distribution and client service teams across the globe... we have a usage range that works very well for our non-U.S. clients... enhanced and extensions are capturing the imagination and satisfying client need.\"</li>\n<li>John Dunn, Evercore: Asked about the domicile mix and demand for non-U.S. exposure. Young responded, \"we have seen a real pickup in interest... in international strategies... not just from our U.S. domiciled clients, but starting to see some of our non-U.S. clients thinking in this more sort of international or ex U.S. space.\"</li>\n<li>Dunn probed on emerging markets. Young explained, \"I think through this year, we are seeing pockets of interest in emerging... we're kind of front and center when folks are thinking about systematic exposure to EM.\"</li>\n<li>Dunn asked about the fee rate. Hynes replied, \"we have seen this direction of travel closer to the mid-30s range... you could see another basis point to come lower perhaps next quarter, particularly if enhanced materializes.\"</li>\n<li>Michael Cyprys, Morgan Stanley: Asked about platform gaps and inorganic vs. organic initiatives. Young indicated a focus on systematic credit, highlighting ongoing track record development and a team led by Scott Richardson.</li>\n<li>Cyprys asked about systematic fixed income. Young asserted confidence in the capability, noting, \"I think we're going to be very well placed over the medium to long term in terms of generating meaningful return for our investors and meaningful cash flows as well.\"</li>\n</ul>\n<h3>Sentiment Analysis</h3>\n<ul>\n<li>Analysts pressed for clarity on pipeline diversity, capital management, and fee dynamics, with a neutral to slightly positive tone supported by continued pipeline strength and product innovation.</li>\n<li>Management maintained a confident and measured tone during prepared remarks, frequently emphasizing discipline, innovation, and robust momentum. In Q&amp;A, management demonstrated openness but used phrases suggesting caution on outlooks, such as \"I think you could continue to see a little bit of downward pressure in the fee rate... but I'll tell you, it's not something that I think we can continue to pencil in necessarily.\"</li>\n<li>Compared to the previous quarter, both analysts and management displayed consistent confidence, though the discussion of fee rate pressure and enhanced equity inflows signaled increased focus on product mix and margins.</li>\n</ul>\n<h3>Quarter-over-Quarter Comparison</h3>\n<ul>\n<li>Guidance for expense and compensation ratios narrowed from previous ranges, with fiscal year 2025 operating expense ratio now expected at 44%–46% versus 45%–47% previously, and the variable compensation ratio at 43%–45% versus 43%–47%.</li>\n<li>Enhanced and extension strategies remained central themes, but there was increased commentary on systematic credit and fixed income initiatives.</li>\n<li>AUM increased from $151.1 billion in Q2 to $166.4 billion in Q3, with continued record net flows, though the pace of net inflows moderated from the record-setting Q2.</li>\n<li>The fee rate discussion indicated potential for modest further downward movement, attributed to product mix changes.</li>\n<li>Management's tone remained confident, but there was greater acknowledgment of competitive and market-driven dynamics affecting product flows and margins.</li>\n<li>Analyst focus shifted slightly more toward geographical mix and platform capabilities, while maintaining interest in pipeline details and capital management.</li>\n</ul>\n<h3>Risks and Concerns</h3>\n<ul>\n<li>Young acknowledged \"crowding in lesser quality high beta stocks created a more challenging environment for Acadian's fundamentally driven quality-orientated approach.\"</li>\n<li>Hynes noted the possibility of further downward pressure on the fee rate, depending on the product mix and pipeline realization.</li>\n<li>Both management and analysts recognized the incubation stage of systematic credit and fixed income strategies, with Young highlighting that \"3-year track records are going to be perhaps more important here than they might be in some other more adjacent areas of our equity business.\"</li>\n</ul>\n<h3>Final Takeaway</h3>\n<p>Acadian Asset Management delivered another quarter of record AUM and strong financial results, driven by enhanced and extension equity strategies as well as a robust, diversified client pipeline. The company added significant distribution resources and continued to expand its product range, particularly in systematic credit and fixed income, while maintaining disciplined capital management and further deleveraging through refinancing. Management expressed confidence in sustaining growth and shareholder value, supported by continued product innovation and a resilient investment process, even as it acknowledged the evolving dynamics around fee rates and market-driven challenges.</p>\n<p><a href=\"https://seekingalpha.com/symbol/aami/earnings/transcripts\">Read the full Earnings Call Transcript</a></p>\n</body></html>",
            "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
            "link": "https://seekingalpha.com/news/4511594-acadian-outlines-record-39b-gross-sales-in-2025-as-aum-reaches-all-time-high-with-enhanced",
            "pub_date": "2025-10-31 01:27:20",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        }
    ]
}